Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Apr 19, 2023
OCGN Sees Impressive 7.12% Profit Thanks to AI Trading Robot

OCGN Sees Impressive 7.12% Profit Thanks to AI Trading Robot

This AI trading robot "Day Trader: Medium Volatility Stocks for Active Trading (TA&FA)", was one of the best in our robot factory, generating a 7.12% gain for OCGN over the course of the previous week.

As per the technical analysis, the Stochastic Oscillator for OCGN moved out of oversold territory on April 13, 2023, which could indicate a shift from a downward trend to an upward trend. This may be considered a bullish signal for traders who may want to buy the stock or buy call options.

Tickeron's A.I.dvisor analyzed 79 instances where the Stochastic Oscillator left the oversold zone and found that in 73 of those cases, the stock price moved higher in the following days. This gives a probability of over 90% for a continued upward trend in the case of OCGN.

However, traders should also consider other factors such as market conditions, company news, and earnings reports before making any investment decisions. It's important to note that short-term gains may not necessarily be sustainable in the long run. Therefore, it's crucial to conduct thorough research and analysis before making any investment decisions.

Day Trader: Medium Volatility Stocks for Active Trading (TA&FA)

Related Ticker: OCGN

Contributor

Dem Sem's AvatarDem Sem|Expert

OCGN in +3.68% Uptrend, growing for three consecutive days on August 26, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where OCGN advanced for three days, in of 233 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where OCGN's RSI Oscillator exited the oversold zone, of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 69 cases where OCGN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 127 cases where OCGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OCGN as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for OCGN turned negative on August 31, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at .

OCGN moved below its 50-day moving average on August 28, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for OCGN crossed bearishly below the 50-day moving average on September 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OCGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

OCGN broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. OCGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (75.758) is normal, around the industry mean (20.457). P/E Ratio (0.000) is within average values for comparable stocks, (27.656). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.558). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (93.458) is also within normal values, averaging (443.914).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OCGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.34B. The market cap for tickers in the group ranges from 58 to 141.42B. VRTX holds the highest valuation in this group at 141.42B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 1%. For the same Industry, the average monthly price growth was 7%, and the average quarterly price growth was 2,392%. QNRX experienced the highest price growth at 64%, while VBIO experienced the biggest fall at -96%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -13%. For the same stocks of the Industry, the average monthly volume growth was -22% and the average quarterly volume growth was 6%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 79
Price Growth Rating: 53
SMR Rating: 94
Profit Risk Rating: 92
Seasonality Score: -8 (-100 ... +100)
View a ticker or compare two or three
OCGN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a company, which engages in the development and commercialization of therapies for eye diseases

Industry Biotechnology

Profile
Details
Industry
N/A
Address
11 Great Valley Parkway
Phone
+1 484 328-4701
Employees
116
Web
https://www.ocugen.com
Interact to see
Advertisement
Exxon Mobil is a global energy giant with roughly 324 billion dollars in trailing revenue, around 29 billion dollars in earnings, record production near 4.7 million barrels per day, and a long runway of projects in Guyana, the Permian, LNG and carbon capture. The Iran war has disrupted shipping through the Strait of Hormuz and could keep a 10–20 dollar‑per‑barrel risk premium in crude if tensions stay high, which would generally be positive for XOM’s upstream earnings and refining margins.
Chevron is a global integrated oil and gas major with growing production, a strong balance sheet, and significant exposure to long‑life projects in the Permian, LNG, and Venezuela, aiming for structurally higher cash flows through 2026 and beyond. The Iran war has increased the probability of supply disruptions or perceived risk in the Gulf, and several analysts warn that Brent could move above 100 dollars per barrel if Hormuz traffic is impaired, which would generally be supportive for Chevron’s earnings and free cash flow.
Shell is a diversified global major with roughly 266.9 billion dollars in trailing revenue, 17.8 billion dollars in earnings, a 3.5% dividend yield, and an active buyback program, trading at about 13 times earnings near its 52‑week high. The Iran war materially raises the risk of disruptions or perceived threats around the Strait of Hormuz, which could push oil well above 80–100 dollars per barrel and tighten LNG markets, a setup that is generally supportive for Shell’s upstream and LNG businesses.
LMT is a defense heavyweight with roughly 75 billion dollars in annual revenue, about 5 billion dollars in earnings, and a backlog above 190 billion dollars spanning fighters, missiles, space, and sustainment contracts that support long‑term cash flow. The U.S.–Iran war has triggered a classic “flight to defense,” with sector ETFs and names like Lockheed rallying as investors price in higher defense spending, missile restocking, and elevated geopolitical risk for years to come.
NOC is a defense heavyweight with about 42 billion dollars in annual revenue, 4.18 billion dollars in earnings, and key growth programs in the B‑21 bomber, Sentinel ICBM, missile defense, and space, which are all strategically prioritized in U.S. and allied budgets. The Iran war has reinforced a rotation into defense stocks as investors expect elevated military spending, ammunition and missile restocking, and sustained demand for advanced systems, and commentary specifically cites Northrop as a likely beneficiary.
RTX is a broad aerospace and defense leader with about 88.6 billion dollars in 2025 revenue, 6.73 billion dollars in earnings, and a 268 billion dollar backlog spanning commercial and defense programs that support multi‑year growth. Management guides to 92–93 billion dollars in 2026 sales, adjusted EPS of 6.60–6.80, and free cash flow of 8.25–8.75 billion dollars, with analysts expecting roughly 6% EPS growth to around 6.67 dollars in 2026.
Delta is the most profitable major U.S. airline, with 2025 operating revenue of 58.3 billion dollars, adjusted EPS of 5.82 dollars, 12% ROIC, and manageable leverage, and it is guiding to 2026 EPS of 6.50–7.50 dollars and 3–4 billion dollars of free cash flow. The Iran war is pushing oil and jet fuel prices higher, with jet fuel benchmarks up about 22% this year amid fears over flows through the Strait of Hormuz, and long‑haul routes across the region are being rerouted, raising costs and causing disruptions.
GD produces business jets, combat vehicles, IT and mission systems, and submarines, with 2025 revenue of 52.55 billion dollars, net income of 4.21 billion dollars, EPS of 15.45, and a sizable backlog near 118 billion dollars that underpins future growth.​ The Iran war has boosted interest in defense stocks; sector ETFs are up double digits this year and analysts emphasize that long‑duration maintenance and modernization contracts can support cash flows even after the conflict cools.
HII is the dominant U.S. Navy shipbuilder, focused on aircraft carriers, submarines, and other major naval vessels, with about 12.0 billion dollars in trailing revenue, 569 million dollars in net income, and EPS of 14.50. The Iran war and threats around the Strait of Hormuz highlight the importance of naval and missile-defense capabilities; reports show interceptor stocks being depleted and stress that keeping sea lanes open will likely require sustained naval investment where HII is a key contractor.
United is a large global carrier with a premium‑focused “United Next” strategy that upgauges to larger, more fuel‑efficient aircraft and adds premium seats to improve margins over the next several years. The Iran war has forced widespread Middle East airspace closures, creating thousands of cancellations, diversions, longer flight times, and higher fuel burn; analysts warn of higher fares and air‑freight rates if the conflict persists.
GE Aerospace is a focused aviation and defense company with two major segments—commercial engines and services, and defense and propulsion—earning most of its profits from long‑duration engine service on an installed base near 80,000 engines. Revenue and earnings growth have been strong, with recent quarterly revenue above 11 billion dollars, up high‑teens year over year, and net income over 2 billion dollars; management guides to 2026 EPS of 7.10–7.40 dollars, well above this year’s roughly 5.4‑dollar consensus.
Shares of Citigroup (C) declined approximately 5.17% in the most recent completed trading session, closing at $110.19 versus a prior close of $116.19. The primary catalyst was hotter-than-expected U.S. Producer Price Index (PPI) data, stoking fears of persistent inflation and a reduced likelihood of near-term Federal Reserve rate cuts.
AVAV surged +16.83% in Monday's session, trading at $294.70 compared to Friday's closing price of $252.25 — a gain of $42.45 per share. The primary catalyst was a powerful confluence of geopolitical demand and corporate developments: the escalating U.S.-Iran military conflict dramatically amplified investor focus on AeroVironment's loitering munitions portfolio.
Shares of Venture Global surged approximately +16.61% on March 2, 2026, closing at $11.30 compared to the prior close of $9.69. The primary catalyst was a stronger-than-expected Q4 2025 earnings report, with GAAP EPS of $0.41 beating the consensus estimate of $0.36 by $0.05.
Shares of CCL plunged 10.11% in Monday's session, falling from a prior close of $31.55 to $28.36. The primary catalyst was a coordinated U.S. and Israeli military strike on Iran over the weekend, causing crude oil prices to surge approximately 8–9% and triggering a global risk-off selloff.
ADT shares dropped sharply — falling as much as 13.4% intraday and hitting a new 52-week low of $6.65 — after reporting Q4 2025 results before the Monday open. Fourth-quarter revenue and guidance both missed analyst expectations, overshadowing an earnings-per-share beat.
Shares of Karman Holdings surged approximately +13.00% in Monday's session, closing near $99.57, up from a prior close of $88.11. The primary catalyst was the release of the company's fourth-quarter and full-year 2025 financial results, which showed strong revenue growth and exceeded top-line expectations.
Netflix dropped out of a months‑long bidding war for Warner Bros Discovery after Paramount/Skydance raised their offer, and Netflix refused to match it, saying the new price was “no longer financially appealing.” The stock jumped roughly 10%+ on the news as investors read this as fiscal discipline—management chose not to overpay, which protects the balance sheet and future returns instead of chasing scale at any price.
SE shares plunged approximately 23% at Tuesday's open, marking one of the steepest single-session selloffs in recent company history. The primary catalyst was a severe Q4 2025 earnings miss: adjusted EPS of $0.63 fell well short of the analyst consensus of $0.80, a miss of roughly 21%.
Shares of Southern Copper Corporation (SCCO) are down 10.32% in Tuesday's session, trading at $196.27 versus the prior close of $218.85 — a single-day loss of $22.58 per share. The primary catalyst is a Bank of America downgrade issued on March 2, cutting SCCO from Neutral to Underperform, which triggered accelerating sell pressure into Tuesday's open.
OCGN Sees Impressive 7.12% Profit Thanks to AI Trading Robot